CLINICAL AND MORPHOLOGICAL RESEARCH INTO THE ROLE OF THE TRANSCRIPTION FACTOR NEUROD1 IN VARIOUS TYPES OF PITUITARY ADENOMAS
O. M. Raspopova, 
L. B. Mitrofanova,
B. E. Galkovsky,
U. A. Tsoy,
U. N. Grineva,
A. A. Palcev,
V. R. Rodichkina
L. B. Mitrofanova,
B. E. Galkovsky,
U. A. Tsoy,
U. N. Grineva,
A. A. Palcev,
V. R. Rodichkina https://doi.org/10.24884/1607-4181-2017-24-3-40-47
Abstract
The role of transcription factors in the pathogenesis of pituitary adenomas is extremely controversial.
The aim of the study was to investigate the role of the transcription factor Neuro D1 in various types of pituitary adenomas.
Materials and methods. A comparative clinico-morphological study was carried out with immunohistochemical analysis and confocal microscopy of the expression of the transcription factor NeuroD1, six adenohypophysis hormones and Ki-67 in 40 pituitary adenomas and 9 normal pituitary glands.
Results. NeuroD1 was expressed in all cases and types of adenomas. The expression level of the transcription factor in adenomas was significantly different from that in the normal pituitary gland (p = 0.006). The average number of cells with expression of NeuroD1 in all tumors was higher than in the normal pituitary gland.
Conclusion. NeuroD1 plays one of the key roles in the pathogenesis of pituitary adenomas, regardless of their hormonal status.About the Authors
O. M. Raspopova
Almazov National Medical Research Centre
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
L. B. Mitrofanova
Almazov National Medical Research Centre
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Lubov B. Мitrofanova.
Akkuratova street, 2, St. Petersburg, 197143
Competing Interests: нет конфликта интересов
B. E. Galkovsky
Almazov National Medical Research Centre
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
U. A. Tsoy
Almazov National Medical Research Centre
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
U. N. Grineva
Almazov National Medical Research Centre
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
A. A. Palcev
Almazov National Medical Research Centre
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
V. R. Rodichkina
Ott Research Institute of Obstetrics and Gynecology
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
References
1. Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J. ((Eds): World Health Organization Classification of Tumors of Endocrine Organs, 4th Edition. IARC Press: Lyon; 2017. 355 p.
2. Suhardja A, Kovacs K, Rutka J. Role of transcription factors in the pathogenesis of pituitary adenomas: a review. J Neurooncol. 2001; 55: 185–193.
3. Asa S.L. Tumors of the pituitary gland. AFIP Atlas of Tumor Pathology. ARP Press: Washington; 2011. 283c.
4. Takahashi Y, Bando H, Iguchi G. A Novel Clinical Entity «Anti-PIT-1 Antibody Syndrome»-Autoimmunity against a Transcription Factor. Rinsho Byori. 2015; 63(4): 491-7 PMID: 26536783
5. Jullien N, Roche C, Brue T et al. Dose-dependent dual role of PIT-1 (POU1F1) in somatolactotroph cell proliferation and apoptosis. PLoS One. 2015; 10(3): e0120010. https://doi.org/10.1371/journal.pone.0120010.
6. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. Published online: 01 august 2017. https://doi.org/10.1007/s12022-017-9498-z
7. Al-Brahim N Y Y, Asa S L. My approach to pathology of the pituitary gland. J Clin Pathol 2006;59:1245–1253
8. Oyama K, Sanno N, Teramoto A et al. Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol. 2001; 14(9): 892-9.
9. Lloyd RV, Jin L, Chandler WF et al. Pituitary specific transcription factor messenger ribonucleic expression in adenomatous and nontumorous human pituitary tissues. Lab Invest. 1993; 69(5): 570-5.
10. Osamura RY, Tahara S, Kurotani R et al. Contributions of immunohistochemistry and in situ hybridization to the functional analysis of pituitary adenomas. J Histochem Cytochem. 2000; 48(4): 445-58.
11. Lamolet B, Pulichino AM, Lamonerie T et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001; 104(6): 849-59.
12. Cooper O, Ben-Shlomo A, Bonert V et al. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010; 1(2): 80-92.
13. Ferretti E, Di Stefano D, Zazzeroni F, Gallo R, et al. Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1. J. of Endocrinological Investigation. 2003; 26(10): 957–965.
14. Poulin G, Turgeon B, Drouin J. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol. 1997; 17(11): 6673-82.
15. Takiguchi T, Koide H, Nagano H, Nakayama A et al. Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing’s disease: a case report. BMC Endocr Disord. 2017;17(1):54. doi: 10.1186/s12902-017-0203-5.
16. Fratticci A1, Grieco FA, Spilioti C, Giangaspero F et al. Differential expression of neurogenins and NeuroD1 in human pituitary tumours. J Endocrinol. 2007;194(3):475-84.
17. Tateno T, Izumiyama H, Doi M, Yoshimoto T et al. Differential gene expression in ACTH-secreting and nonfunctioning pituitary tumors. Eur J Endocrinol. 2007;157: 717–724.
18. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414:788–791.
19. Cerf ME. Transcription factors regulating beta-cell function. Eur J Endocrinol 2006; 155: 671–679.
20. Lee JE, Hollenberg SM, Snider L, Turner DL et al. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science. 1995; 268:836–844.
21. Malecki MT, Jhala US, Antonellis A, Fields L, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999; 23:323–328.
22. Sharma A, Moore M, Marcora E, Lee JE et al. The Neuro D1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/CREB binding protein binding. Mol Cell Biol. 1999; 19: 704–713.
23. Moates JM, Nanda S, Cissell MA, Tsai MJ, Stein R. BETA2 activates transcription from the upstream glucokinase gene promoter in islet beta-cells and gut endocrine cells. Diabetes. 2003; 52:403–408.
24. Mutoh H, Naya FJ, Tsai MJ, Leiter AB. The basic helixloop-helix protein BETA2 interacts with p300 to coordinate differentiation of secretin-expressing enteroendocrine cells. Genes Dev. 1998;12:820–830.
25. Konishi Y, Ohkawa N, Makino Y, Ohkubo H et al. Transcriptional regulation of mouse type 1 inositol 1,4,5-trisphosphate receptor gene by NeuroD-related factor. J Neurochem 1999;72:1717–1724.
26. Liu M, Pereira FA, Price SD, Chu MJ et al. Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. Genes Dev. 2000;14: 2839–2854.
Review
For citations:
Raspopova O.M., Mitrofanova L.B., Galkovsky B.E., Tsoy U.A., Grineva U.N., Palcev A.A., Rodichkina V.R. CLINICAL AND MORPHOLOGICAL RESEARCH INTO THE ROLE OF THE TRANSCRIPTION FACTOR NEUROD1 IN VARIOUS TYPES OF PITUITARY ADENOMAS. The Scientific Notes of the Pavlov University. 2017;24(3):40-47. (In Russ.) https://doi.org/10.24884/1607-4181-2017-24-3-40-47
Views:
776
Email this article 